U.S. Markets close in 3 hrs 22 mins

Free Stock Performance Review on Array BioPharma and Three More Biotech Industry

Stock Research Monitor: ITCI, ARGS, and AUPH

LONDON, UK / ACCESSWIRE / May 16, 2018 / If you want a free Stock Review on ARRY sign up now at www.wallstequities.com/registration. On Tuesday, the NASDAQ Composite ended the day at 7,351.63, down 0.81%; the Dow Jones Industrial Average edged 0.78% lower, to finish at 24,706.41; and the S&P 500 closed at 2,711.45, marginally slipping 0.68%. Losses were broad based as all sectors finished the trading session in red. WallStEquities.com has initiated research reports on the following Biotechnology stocks: Intra-Cellular Therapies Inc. (NASDAQ: ITCI), Argos Therapeutics Inc. (NASDAQ: ARGS), Array BioPharma Inc. (NASDAQ: ARRY), and Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH). All you have to do is sign up today for this free limited time offer by clicking the link below.


Intra-Cellular Therapies

New York headquartered Intra-Cellular Therapies Inc.'s stock finished Tuesday's session 0.77% higher at $20.93 with a total trading volume of 244,492 shares. The stock has gained 18.05% over the past three months and 87.54% in the previous twelve months. The Company's shares are trading above their 50-day and 200-day moving averages by 1.20% and 20.75%, respectively. Moreover, shares of Intra-Cellular Therapies, which engages in developing novel drugs for the treatment of neuropsychiatric and neurodegenerative diseases, have a Relative Strength Index (RSI) of 57.90. Get the full research report on ITCI for free by clicking below at:


Argos Therapeutics

Shares in Durham, North Carolina-based Argos Therapeutics Inc. rose 2.68%, ending yesterday's session at $0.19 with a total trading volume of 30,752 shares. The Company's shares are trading below their 50-day moving average by 75.79%. Moreover, shares of Argos Therapeutics, which focuses on the development and commercialization of individualized immunotherapies for the treatment of cancer and infectious diseases in North America, have an RSI of 27.31. Gain free access to the research report on ARGS at:


Array BioPharma

On Tuesday, Boulder, Colorado headquartered Array BioPharma Inc.'s stock saw a decline of 2.60%, to close the day at $15.36. A total volume of 2.09 million shares was traded. The Company's shares have advanced 86.86% over the last twelve months. The stock is trading above its 200-day moving average by 19.06%. Additionally, shares of Array BioPharma, which focuses on the discovery, development, and commercialization of small molecule drugs to treat patients with cancer in North America, Europe, and Asia/Pacific, have an RSI of 56.34. Register for your free report coverage on ARRY at:


Aurinia Pharmaceuticals

Shares in Victoria, Canada headquartered Aurinia Pharmaceuticals Inc. ended the day 0.80% higher at $6.28. A total volume of 1.56 million shares was traded, which was above their three months average volume of 613.88 thousand shares. The stock has gained 15.65% in the last month and 19.62% in the previous three months. The Company's shares are trading above their 50-day and 200-day moving averages by 16.95% and 11.93%, respectively. Furthermore, shares of Aurinia Pharma, which engages in the development of a therapeutic drug to treat autoimmune diseases in Canada and internationally, have an RSI of 77.65. Get the free research report on AUPH at:


Wall St. Equities:

Wall St. Equities (WSE) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. WSE has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.

WSE has not been compensated; directly or indirectly; for producing or publishing this document.


The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third-party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email info@wallstequities.com. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by WSE. WSE is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.


WSE, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. WSE, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, WSE, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.


This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither WSE nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit



For any questions, inquiries, or comments reach out to us directly. If you're a company, we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:

Email: info@wallstequities.com

Phone number: 21 32 044 483

Office Address: 1 Scotts Road #24-10, Shaw Center Singapore 228

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: Wall St. Equities